MITO News

Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018 financials, which saw sales growth of 8% and 14%, respectively. That's especially impressive given the current...read more

Stealth BioTherapeutics, a Phase 3 biotech focused on rare diseases caused by mitochondrial dysfunction, raised $78 million by offering 6.5 million shares at $12, the low end of the range of $12 to $14. Stealth BioTherapeutics plans to list on the Nasdaq under the symbol MITO. Jefferies, Evercore ISI and BMO Capital Markets acted as lead managers on the deal. ...read more

Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six combined. These others are mostly small healthcare IPOs: ...read more

Stealth BioTherapeutics, a Phase 3 biotech focused on mitochondrial dysfunction, announced terms for its IPO on Wednesday. The Newton, MA-based company plans to raise $81 million by offering 6.2 million ADSs at a price range of $12 to $14. Insiders intend to purchase $60 million worth of ADSs in the offering (74% of the deal). At the midpoint of the proposed range,...read more